Institute of Biomedical Research Corp. (MRES)
USD 0.01
(-26.32%)
USD 0.01
(-26.32%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2010 | 401.84 Thousand USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 141.17 Thousand USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2010 Q2 | 1.55 Million USD | 287.97% |
| 2010 FY | 401.84 Thousand USD | 0.0% |
| 2010 Q3 | 1.58 Million USD | 1.48% |
| 2010 Q4 | 461.33 Thousand USD | -70.84% |
| 2010 Q1 | 401.84 Thousand USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 FY | - USD | -100.0% |
| 2007 Q1 | - USD | -100.0% |
| 2007 Q3 | - USD | -100.0% |
| 2007 Q2 | 172.49 Thousand USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2006 Q3 | 55.00 USD | -99.96% |
| 2006 Q4 | 168.96 Thousand USD | 307114.55% |
| 2006 Q2 | 156.92 Thousand USD | 11.16% |
| 2006 Q1 | 141.17 Thousand USD | 4.97% |
| 2006 FY | 141.17 Thousand USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | 1690.00 USD | 0.0% |
| 2005 Q4 | 134.49 Thousand USD | 7858.05% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.025% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 90.251% |
| SQZ Biotechnologies Company | 27.47 Million USD | 98.537% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.074% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 98.65% |
| Mesoblast Limited | 118.7 Million USD | 99.661% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 57.623% |
| Genus plc | 233.1 Million USD | 99.828% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 86.287% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 70.091% |
| Marizyme, Inc. | 18.71 Million USD | 97.853% |
| ContraFect Corporation | 2.88 Million USD | 86.052% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 46.42% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -196.596% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 72.216% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 82.723% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 92.898% |
| MultiCell Technologies, Inc. | 202.58 USD | -198265.584% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.301% |
| EV Biologics, Inc. | 1.49 Million USD | 73.116% |
| Q BioMed Inc. | 4.1 Million USD | 90.223% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 98.786% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 36.222% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 67.286% |
| Biomind Labs Inc. | 735.54 Thousand USD | 45.367% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.766% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 96.908% |
| Skye Bioscience, Inc. | 4.61 Million USD | 91.293% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 54.75% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -183.956% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 93.155% |
| IMV Inc. | 28.88 Million USD | 98.609% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -1462.46% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 82.206% |
| GB Sciences, Inc. | 1.75 Million USD | 77.159% |
| Alpha Cognition Inc. | 1.22 Million USD | 67.072% |
| HST Global, Inc. | 98.31 Thousand USD | -308.72% |
| CSL Limited | 12.18 Billion USD | 99.997% |
| Halberd Corporation | 150 Thousand USD | -167.899% |
| Enzolytics Inc. | 996.33 Thousand USD | 59.667% |
| Resverlogix Corp. | 6.49 Million USD | 93.809% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 15.843% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -57.223% |
| argenx SE | 20 Million USD | 97.991% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.118% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 85.165% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -3830.064% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.904% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -100.308% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 83.24% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -75.257% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.406% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 86.721% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -11.715% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 98.023% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -170.325% |
| BioStem Technologies, Inc. | 4.71 Million USD | 91.471% |
| ONE Bio Corp. | 19.71 Million USD | 97.962% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -60.623% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -61.567% |
| Agentix Corp. | 50 Thousand USD | -703.698% |
| LadRx Corporation | 33.6 Thousand USD | -1095.766% |
| Cell Source, Inc. | 9.25 Million USD | 95.658% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 46.86% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 46.86% |
| NovAccess Global Inc. | 2.19 Million USD | 81.733% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 94.318% |
| Itoco Inc. | 228.37 Thousand USD | -75.959% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -90.472% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 91.936% |
| Kadimastem Ltd | 891.22 Thousand USD | 54.911% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| CytoDyn Inc. | 30.07 Million USD | 98.664% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 17.022% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -14.211% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 94.861% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -228.04% |
| Rebus Holdings, Inc. | 310 Thousand USD | -29.629% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 91.514% |
| International Stem Cell Corporation | 4.17 Million USD | 90.382% |
| Bioxytran, Inc. | 1.92 Million USD | 79.125% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -543.855% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 81.574% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 95.168% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 95.319% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 74.166% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -49.944% |
| Neutra Corp. | 54.15 Thousand USD | -642.021% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 78.041% |
| PureTech Health plc | 25.51 Million USD | 98.425% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 67.175% |
| IXICO plc | 472.02 Thousand USD | 14.867% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 97.408% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.355% |
| CSL Limited | 12.18 Billion USD | 99.997% |
| Cellectis S.A. | 92.77 Million USD | 99.567% |